Number | |
---|---|
Sex | |
Male | 46 |
Female | 14 |
Age (years) | |
Median | 70 |
Range | 32–81 |
Histological type | |
Adenocarcinoma | 27 |
Squamous cell carcinoma | 27 |
Pleomorphic carcinoma | 3 |
Adenosquamous cell carcinoma | 2 |
Large cell carcinoma | 1 |
Size of primary tumor (mm) | |
Median | 35 |
Range | 13–88 |
Clinical T status | |
T1 | 16 |
T2 | 29 |
T3 | 14 |
T4 | 1 |
CEA (ng/mL) | |
Median | 4.8 |
Range | 1.5–152.2 |
SCC (ng/mL) | |
Median | 0.8 |
Range | 0.0–19.7 |
CYFRA (ng/mL) | |
Median | 2.48 |
Range | 0.59–53.08 |
FDG-PET | |
Number of patients | 35 |
Median of SUVmax | 6 |
Range of SUVmax | 0–22.78 |
FDG-PET/CT | |
Number of patients | 25 |
Median of SUVmax | 11.45 |
Range of SUVmax | 1.90–52.60 |
Surgical approach | |
VATS | 23 |
Thoracotomy | 20 |
Conversion (VATS to thoracotomy) | 17 |
Operative procedure | |
Pneumonectomy | 7 |
Lobectomy | 51 |
+ bronchoplasty | 3 |
+ angioplasty | 1 |
+ bronchoplasty & angioplasty | 2 |
Segmentectomy | 2 |
Pathological T status | |
pT1 | 15 |
pT2 | 29 |
pT3 | 14 |
pT4 | 2 |
Pathological N status | |
pN0 | 23 |
pN1 | 22 |
pN2 | 15 |
Pathological stage | |
IA | 4 |
IB | 12 |
IIA | 14 |
IIB | 6 |
IIIA | 23 |
IIIB | 1 |